For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
HIV: Beyond undetectability
With Dr. Réjean Thomas and Prof. Yazdan Yazdanpanah
After clicking PLAY, click on the lower bar’s subtitles icon [CC] for english subtitles.
- Today, the average age of people living with HIV is 50 years
- The life expectancy of PLHIV whose viral load is undetectable is approching the same as that of HIV-negative people
- Among PLHIV whose virus is controlled, certain comorbidities are decreasing
- Research is focused on developing therapies with less toxicity, including TAF
This activity is supported by an educational grant from:
HIV Beyond Undetectable
Today, with treatments being more effective and better tolerated, people living with HIV (PLHIV) whose viral load is undetectable, who are in the health care system and have no comorbidities have roughly the same life expectancy as HIV-negative people. Yet with the aging HIV population, we are seeing the appearance or increase of comorbidities associated with aging.
In the past, if we believed that PLHIV aged prematurely and were more likely to develop certain diseases, recent studies show that the comorbidity rate is decreasing among patients whose virus is controlled. The risk difference between PLHIV and HIV-negative people is narrowing, particularly with regard to cancer, neurocognitive impairment and cardiovascular disease, probably owing to the optimization of treatments.
However, this is less the case with regard to kidney disease and bone problems, as well as hepatitis C, mainly because of similar risk factors to HIV. In this regard, the search continues for new treatments with less toxicity. TAF is one example.
Réjean Thomas, MD, Dhc
CEO – Founder
Clinique médicale l’Actuel:
Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Yazdan Yazdanpanah, MD, PhD
Tropical and Infectious Diseases
Hôpital Bichat – Claude-Bernard
AND THE SUPPORT OF:
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation with:
Advisory boards: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare
Yazdan Yazdanpanah, MD, PhD has a financial interest/relationship or affiliation with:
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.